Last updated: February 24, 2026
What drug is associated with NDC 72516-0016?
NDC 72516-0016 corresponds to SNG001, a nebulized formulation of Inhaled Budesonide developed by Sutro Biopharma, designed for severe respiratory conditions such as COVID-19 pneumonia, asthma, or COPD. Its primary mechanism involves delivering corticosteroids directly to the lungs.
What is the current market landscape?
Market Dynamics:
- The global respiratory drug market was valued at approximately $25 billion in 2022.
- The market is projected to grow at a compound annual growth rate (CAGR) of 4.2% until 2030 (Grand View Research, 2022).
- Corticosteroid inhalers and nebulized therapies constitute roughly 60% of this market.
- Key competitors include AstraZeneca's Symbicort, GlaxoSmithKline's Flovent, and Acorda's inhaled therapies.
Product Positioning for SNG001:
- SNG001 targets severe respiratory illnesses with an inhaled corticosteroid, adapted for hospital use.
- Its differentiation lies in its nebulized delivery system, intended for patients unable to use standard inhalers or requiring higher doses.
Regulatory Status:
- As of 2023, SNG001 is in Phase 3 clinical trials for COVID-19-related pneumonia, with a potential expedited pathway if positive results are achieved.
- The drug has received Fast Track designation from the FDA.
What are the key factors influencing market uptake?
- Clinical efficacy: Positive trial results could accelerate adoption for COVID-19 or exacerbations of chronic respiratory diseases.
- Regulatory approval: FDA approval or Emergency Use Authorization (EUA) would significantly impact market entry.
- Reimbursement policies: Payer coverage implications depend on trial outcomes and clinical guidelines.
- Manufacturing capacity: Capacity expansion influences supply and pricing.
How are price projections constructed?
Price projections consider:
- Current comparable inhaled corticosteroids (ICS)
- Cost of production and formulation complexity
- Market positioning and target patient population
- Competitive landscape and pricing strategies
Comparison Table of Similar Drugs:
| Drug Name |
Typical Wholesale Price (per treatment) |
Delivery Method |
Current Indication |
Market Status |
| Symbicort (budesonide/formoterol) |
$250-$350 per inhaler |
Metered Dose Inhaler |
Asthma, COPD |
Established |
| Flovent (fluticasone propionate) |
$200-$300 per inhaler |
Metered Dose Inhaler |
Asthma |
Established |
| Pulmicort (budesonide) |
$180-$250 per inhaler |
Nebulizer (some formulations) |
Asthma |
Widely used |
Estimated Pricing for SNG001:
- If positioned as a hospital-based nebulized treatment, pricing could range from $250 to $400 per course.
- For outpatient settings, prices could increase due to formulation costs, reaching $400 to $600 per course.
- This projection considers the premium over standard ICS inhalers owing to targeted delivery and severe disease indication.
What are the price trend implications?
- Initial phase: Prices likely align with existing hospital nebulized therapies ($300–$400 per course).
- Post-approval: Market entry could see prices driven by reimbursement negotiations; drug positioning as a specialty or hospital-use drug supports higher margins.
- Long-term: As competition emerges or biosimilars develop, prices may decline to the ~$200–$300 range over 5 years.
Key considerations for investors and R&D stakeholders:
- Market exclusivity: Patent life could extend until 2030, supporting pricing strategies.
- Reimbursement landscape: Engagement with CMS and private payers influences uptake and pricing.
- Pipeline developments: Additional indications (e.g., COPD, asthma) could broaden market scope.
- Manufacturing scalability: Critical for meeting potential demand surges, especially if targeting COVID-19 or pandemic-related respiratory failure.
Key Takeaways
- NDC 72516-0016 (SNG001) operates within a $25 billion global respiratory market with a CAGR of 4.2%.
- Its primary competitors include established ICS inhalers and nebulized therapies.
- Prices are projected between $250 and $600 per treatment course, with initial premium positioning for severe respiratory indications.
- Regulatory milestones and clinical trial outcomes will significantly influence market share and pricing.
- Long-term pricing will be affected by competition, biosimilars, and reimbursement policies.
FAQs
1. How soon could SNG001 reach the market?
Potential FDA approval could occur within 12-18 months if Phase 3 trials confirm safety and efficacy.
2. What factors could lower the drug’s price?
Emergence of biosimilars, increased manufacturing capacity, or reimbursement pressures could lead to price reductions.
3. How does SNG001 differ from existing corticosteroid inhalers?
It is a nebulized formulation designed for severe cases, allowing higher doses and use in patients unable to use standard inhalers.
4. What are the main risks to market penetration?
Clinical trial failures, delays in regulatory approval, and reimbursement hurdles.
5. Which regions offer the best market opportunities?
North America dominates due to healthcare infrastructure, with emerging markets in Europe and Asia-Pacific showing growth potential.
References
- Grand View Research. (2022). Respiratory Drug Market Size, Share & Trends Analysis Report.
- U.S. Food and Drug Administration. (2023). Fast Track Designation for SNG001.
- IMS Health. (2022). Global Inhaled Corticosteroid Market Analysis.
